WAVRE, Belgium — 31 October 2023: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces that the first patients in Ireland have been implanted with MINIject®, expanding the commercial rollout of the Company’s minimally-invasive glaucoma surgery (MIGS) device across Europe.
Glaucoma is the leading cause of blindness in Ireland, with the incidence of the condition expected to rise by 33% over the coming decade. Patients in Ireland with open-angle glaucoma will now have available to them, a powerful new treatment option and will be able to benefit from the many advantages offered by MINIject® compared to traditional treatment methods. Currently the only commercially available supraciliary MIGS implant, MINIject® has demonstrated meaningful and sustained performance, combined with a favorable safety profile.
Patients were successfully implanted with MINIject® at the IOES (Institute of Eye Surgery), Mullingar, by Mr. Anish Dhital. This follows iSTAR Medical’s recent expansion of MINIject® into other European countries including Sweden and Norway.
Mr. Anish Dhital, Cataract and Glaucoma Specialist at the IOES (Mullingar) said:
Michel Vanbrabant, CEO of iSTAR Medical, commented:
About iSTAR Medical
iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs.
iSTAR Medical is an independent company which entered a strategic partnership with AbbVie (NYSE: ABBV) in July 2022. The collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates iSTAR Medical’s goal to bring MINIject® to more patients globally while providing AbbVie the opportunity to further expand its diverse eye care portfolio.
MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.
Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[2,3] IOP reduction, through medication or surgery, helps delay disease progression. Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.[3,4] Invasive surgery can present risks with irreversible complications and often requires long-term patient management.[3,4] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile. MINIject is potentially best-in-class for its promising long-term efficacy and safety.
 Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93
 Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021.
 “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73